All patients (n = 37) Patients with FeNO<37 ppb (n = 25) Patients with FeNO ≥37 ppb (n = 12) p-Value
Age (years) 61(49-69) 61(39-68) 65(53-70) 0.3379
Gender, male/female 15/22 10/15 5/7 0.9230
Body mass index (kg/m2) 23.0(19.4-25.4) 23.4(19.4-26.1) 21.9(19.7-24.6) 0.6037
Atopic/nonatopic 27/10 18/7 9/3 0.8475
Non/ex-smokers 29/8 20/5 9/3 0.7295
Duration of asthma, years 5.0(1.0-14.0) 5.0(2.0-16.0) 4.5(1.0-10.0) 0.2032
Coexisting allergic rhinitis 16 8 8* 0.0463
ACQ5, overall score 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.1) 0.5040
FVC, L 3.14(2.58-3.70) 3.02(2.43-3.44) 3.47(2.67-4.05) 0.2427
%FVC (% predicted) 106.2(88.6-113.5) 97.9(88.0-109.6) 115.8(104.6-134.2) 0.0071
FEV1, L 2.38(1.80-2.91) 2.36(1.80-2.91) 2.43(1.86-2.97) 0.6731
%FEV1 (% predicted) 89.4(80.6-108.2) 88.2(80.6-105.1) 106.2(79.1-112.0) 0.2561
%FEF50%(% predicted) 63.1(43.3-94.2) 64.0(47.8-102.9) 57.7(40.0-91.9) 0.3636
%FEF75%(% predicted) 45.5(29.0-76.6) 46.5(34.8-81.1) 37.4(25.8-62.5) 0.1630
PEF variability, % 3.3(2.0-4.8) 3.3(2.0-5.7) 2.7(1.8-4.6) 0.6063
Min%Max PEF, % 90.2(87.7-93.0) 90.3(87.1-93.0) 90.0(87.8-94.8) 0.8539
FeNO, ppb 28.0(18.5-38.5) 20.0(18.0-28.0) 51.5(40.8-57.5) <0.0001
Data are expressed as the medians (interquartile ranges).
Abbreviations: ACQ5: Asthma Control Questionnaire, 5-item version; FEF50%:Forced Expiratory Flow at 50% of FVC; FeNO: Fractional Exhaled Nitric Oxide; FEV1:Forced Expiratory Volume In 1 Second; FVC:Forced Vital Capacity;Min%Max PEF:The Lowest PEF over A Week Expressed as the Percentage of the Highest PEF; PEF:Peak Expiratory Flow.*p <0.05 versus patients with FeNO<37 ppb.
Table 1: Characteristics of the study subjects at baseline.
Goto home»